Methods for identification of modulators of OSGPR116 activity, and their use in the treatment of disease

Abstract

This invention relates to the identification of fatty acid or lipid amides that decrease food intake in mammals, including fatty acid ethanolamides, as ligands for the G-protein coupled receptor OSGPR116, and describes the first demonstration of a specific G-protein coupled receptor that is activated by fatty acid ethanolamides that inhibit feeding. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR116, and new pharmaceutical agents identified by these methods. It is also directed to the use of such agents in the manufacture of medicaments for the treatment of OSGPR116 mediated diseases, and methods of treating diseases such as obesity and diabetes by administering to an individual a therapeutic amount of a modulator of OSGPR116 identified by these methods.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application No. 60 / 469,484, filed May 9, 2003, which is herein incorporated by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] Not applicable. REFERENCE TO SEQUENCE LISTING [0003] A complete sequence listing section is included herein. BACKGROUND OF THE INVENTION [0004] This invention relates to the identification of fatty acid or lipid amides as ligands of the G-protein coupled receptor OSGPR116, and is directed to in vitro methods for screening candidate drugs for their ability to modulate the activity of OSGPR116, and to methods of treating disease by administering to an individual a therapeutic amount of a modulator of OSGPR116. [0005] G-protein coupled receptors (GPCRs) are a super-family of membrane receptors that mediate a wide variety of biological functions. Upon binding of extracellular ligands, GPCRs interact with a specif...

AI Technical Summary

Benefits of technology

[0008] The present invention is based on the finding that the G-protein coupled receptor OSGPR116 is able to act as a receptor for fatty acid or lipid amides and that cells transfected to express OSGPR116 gain the ability to elicit Gi / o (i.e. Gi and / or Go) G-protein mediated responses following exposure to fatty acid or lipid amides. Suitable lipid or fatty acid amides include fatty acid alkanolamides, including fatty acid ethanolamides. In one embodiment, lipid amides are selected from oleoyl ethanolamide, palmitoyl ethanolamide, stearoyl ethanolamide, linoleoyl ethanolamide, linolenoyl ethanolamide and oleamide, or a functional analog or homolog of one of these compounds. Identification of a ligand for OSGPR116 therefore facilitates the development of screening methods for identifying modulators of the OSGPR116 receptor.

Problems solved by technology

There is unquestionably a great unmet need for new drugs for the treatment of obesity, and thus amelioration of diseases associated with this condition, e.g. diabetes, cardiovascular diseases.

Additional appetite suppressants dexfenfluramine, fenfluramine and, phentermine have been withdrawn following reports of valvular heart disease associated with their use; these drugs were also associated with the rare but serious risk of pulmonary hypertension.

However, the molecular mechanism of fatty acid ethanolamides in modulating food intake has not been elucidated.

Consequently there are considerable problems associated with developing such compounds of unknown mechanism of action.

Images